electroCore, Inc.

Stage 2 · Advancing · week 8

As of Oct 22, 2026, electroCore is in Stage 2, the uptrend phase, now in week 8 (since Aug 31, 2026). It closed at $7.41, 39.7% below its 52-week high and below its 200-day average, which is rising.

$7.41

+1.51% today

$66.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is ECOR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 22w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 2w → S1 2w → S2 13w → S3 4w → S2 13w → S3 7w → S2 9w → S3 1w → S4 8w → S1 2w → S2 22w → S3 5w → S4 13w → S1 6w → S4 10w → S1 4w → S4 4w → S1 4w → S2 9w → S3 2w → S2 2w → S3 2w → S2 9w → S3 4w → S2 8w current

Total tracked: 165 weeks across 25 stage runs.

ECOR among Medical Devices13th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…13	ECORelectroCore, Inc.	Stage 2 · wk 8	86	−35.1%

vs 52W High

-39.7%

$4.42 lo$12.29 hi

39.7% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 8

1w13w26w

Week 8, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-3.5%

200 DMA: $7.68 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.44x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-35.1%

+19.7%

+19.9%

YTD

+62.9%

+49.1%

Scan Membership

Breakout Watch

Latest: 2024-10-16

7 appearances in last 60 days. First seen: 2020-08-04.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 8 · Vol 0.44x

2026-10-21S2

Wk 8 · Vol 0.59x

2026-10-20S2

Wk 8 · Vol 0.64x

2026-10-19S2

Wk 7 · Vol 0.80x

2026-10-16S2

Wk 7 · Vol 1.57x

2026-10-15S2

Wk 7 · Vol 1.05x

2026-10-14S2

Wk 7 · Vol 1.31x

2026-10-13S2

Wk 7 · Vol 2.06x

2026-10-12S2

Wk 6 · Vol 0.62x

2026-10-09S2

Wk 6 · Vol 0.50x

2026-10-08S2

Wk 6 · Vol 0.59x

2026-10-07S2

Wk 6 · Vol 0.55x

Moving averages & range

50 DMA

$9.80

200 DMA

$7.68

52W High

$12.29

52W Low

$4.42

5D Low

$7.30

Resistance levels (recent highs)

20d High

$11.12

60d High

$12.29

120d High

$12.29

250d High

$12.29

Next resistance

+50.1%

to 20d High

Dividend Yield

0.00%

P/B -23.9

electroCore: quick answers

What stage is electroCore in?

As of Oct 22, 2026, electroCore (ECOR) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 31, 2026 and is in week 8. What the four stages mean

Is electroCore in an uptrend?

Yes. electroCore is in a Stage 2 uptrend. It trades 3.5% below its 200-day average, which is rising.

How far is electroCore from its 52-week high?

electroCore closed at $7.41 on Oct 22, 2026, 39.7% below its 52-week high of $12.29. Its 52-week low is $4.42.

How has electroCore performed over the past year?

As of Oct 22, 2026, electroCore is up 49.1% over the past year and up 62.9% so far in 2026.

Which sector and industry is electroCore in?

electroCore is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.